Review Article | Published:

Mechanisms of central tolerance for B cells

Nature Reviews Immunology volume 17, pages 281294 (2017) | Download Citation

Abstract

Immune tolerance hinders the potentially destructive responses of lymphocytes to host tissues. Tolerance is regulated at the stage of immature B cell development (central tolerance) by clonal deletion, involving apoptosis, and by receptor editing, which reprogrammes the specificity of B cells through secondary recombination of antibody genes. Recent mechanistic studies have begun to elucidate how these divergent mechanisms are controlled. Single-cell antibody cloning has revealed defects of B cell central tolerance in human autoimmune diseases and in several human immunodeficiency diseases caused by single gene mutations, which indicates the relevance of B cell tolerance to disease and suggests possible genetic pathways that regulate tolerance.

Key points

  • B cell central tolerance is regulated by the mechanisms of receptor editing and apoptosis, which operate in succession over the course of 2 to 3 days.

  • Receptor editing involves ongoing immunoglobulin light chain gene recombination, leading to secondary rearrangements that can alter antigen receptor specificity by replacing one light chain with another.

  • B cell receptor (BCR) tonic signalling in immature B cells promotes the positive selection of cells with unligated receptors through a phosphoinositide 3-kinase (PI3K)-dependent pathway, whereas BCR ligation promotes negative selection, in part through hindering this pathway and probably also by downregulating BCR levels.

  • Increasing numbers of single gene defects have been described that hinder central tolerance in B cells in mice and humans

  • Novel screens for central tolerance are now possible that can be applied to mouse or human B cells, including in humanized mouse models.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. J. Exp. Med. 207, 173–174 (2010).

  2. 2.

    et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis. J. Clin. Invest. 123, 3074–3083 (2013).

  3. 3.

    et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. Proc. Natl Acad. Sci. USA 111, E2567–E2575 (2014).

  4. 4.

    et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 334, 676–682 (1988). A monumental paper that uses immunoglobulin transgenic mice to show that clonal anergy is a mechanism of B cell tolerance.

  5. 5.

    The “clonal selection hypothesis” and current concepts of B cell tolerance. Immunity 5, 189–195 (1996).

  6. 6.

    et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat. Immunol. 11, 635–643 (2010).

  7. 7.

    Somatic generation of antibody diversity. Nature 302, 575–581 (1983).

  8. 8.

    , , , & Molecular components of the B-cell antigen receptor complex of the IgM class. Nature 343, 760–762 (1990).

  9. 9.

    Antigen receptors on B lymphocytes. Annu. Rev. Immunol. 10, 97–121 (1992).

  10. 10.

    & Oligomeric organization of the B-cell antigen receptor on resting cells. Nature 467, 465–469 (2010).

  11. 11.

    & Polyreactive antibodies: function and quantification. J. Infect. Dis. 212 (Suppl. 1), S42–S46 (2015).

  12. 12.

    Transgenic mice with immunoglobulin genes. Annu. Rev. Immunol. 5, 151–174 (1987).

  13. 13.

    & Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 337, 562–566 (1989). The first evidence for clonal deletion in B cell central tolerance.

  14. 14.

    & Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras. Proc. Natl Acad. Sci. USA 86, 8039–8043 (1989).

  15. 15.

    et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353, 765–769 (1991).

  16. 16.

    et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 72, 325–335 (1993).

  17. 17.

    et al. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature 349, 331–334 (1991). The first evidence for negative regulation of B cells reactive to antigens that are relevant to autoimmune disease.

  18. 18.

    & The regulation of lupus-associated autoantibodies: immunoglobulin transgenic models. Curr. Opin. Immunol. 15, 709–717 (2003).

  19. 19.

    , & Receptor editing in self-reactive bone marrow B cells. J. Exp. Med. 177, 1009–1020 (1993).

  20. 20.

    , , & Receptor editing: an approach by autoreactive B cells to escape tolerance. J. Exp. Med. 177, 999–1008 (1993). References 19 and 20 provide the first evidence for receptor editing in B cells.

  21. 21.

    Receptor editing in lymphocyte development and central tolerance. Nat. Rev. Immunol. 6, 728–740 (2006).

  22. 22.

    , , & B lymphocytes may escape tolerance by revising their antigen receptors. J. Exp. Med. 177, 1165–1173 (1993).

  23. 23.

    & Light chain replacement: a new model for antibody gene rearrangement. J. Exp. Med. 182, 541–548 (1995). The first targeted transgenic model for immunoglobulin L chain shows that secondary rearrangements can edit a functional L chain gene in the physiological context.

  24. 24.

    , & Editing disease-associated autoantibodies. Immunity 6, 97–105 (1997).

  25. 25.

    et al. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 7, 765–775 (1997).

  26. 26.

    , & Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat. Immunol. 5, 645–650 (2004). This paper provides strong evidence for the remarkable efficiency of receptor editing in rescuing autoreactive B cells.

  27. 27.

    et al. B cell deletion, anergy, and receptor editing in “knock in” mice targeted with a germline-encoded or somatically mutated anti-DNA heavy chain. J. Immunol. 161, 4634–4645 (1998).

  28. 28.

    et al. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J. Immunol. 175, 909–916 (2005).

  29. 29.

    et al. Contribution of receptor editing to the antibody repertoire. Science 291, 1541–1544 (2001).

  30. 30.

    & Reduced life span of anergic self-reactive B cells in a double-transgenic model. J. Exp. Med. 179, 125–134 (1994).

  31. 31.

    , & Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371, 389–395 (1994).

  32. 32.

    , , , & Control systems and decision making for antibody production. Nat. Immunol. 11, 681–688 (2010).

  33. 33.

    Allelic exclusion of immunoglobulin gene rearrangement and expression: why and how? Semin. Immunol. 14, 207–212 (2002).

  34. 34.

    et al. Allelic exclusion in transgenic mice that express the membrane form of immunoglobulin mu. Science 236, 816–819 (1987).

  35. 35.

    & Frequency and characterization of phenotypic Ig heavy chain allelically included IgM-expressing B cells in mice. J. Immunol. 164, 893–899 (2000).

  36. 36.

    et al. Pro-B cells sense productive immunoglobulin heavy chain rearrangement irrespective of polypeptide production. Proc. Natl Acad. Sci. USA 108, 10644–10649 (2011).

  37. 37.

    et al. RAG-1 and ATM coordinate monoallelic recombination and nuclear positioning of immunoglobulin loci. Nat. Immunol. 10, 655–664 (2009).

  38. 38.

    , & Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 9, 195–205 (2009).

  39. 39.

    et al. Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J. 3, 1209–1219 (1984).

  40. 40.

    , , & Surrogate light chain expression is required to establish immunoglobulin heavy chain allelic exclusion during early B cell development. Immunity 4, 133–144 (1996).

  41. 41.

    , , , & VpreB1/VpreB2/lambda 5 triple-deficient mice show impaired B cell development but functional allelic exclusion of the IgH locus. J. Immunol. 168, 6286–6293 (2002).

  42. 42.

    ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat. Rev. Immunol. 6, 283–294 (2006).

  43. 43.

    , & In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073–1083 (1997).

  44. 44.

    et al. Interference with immunoglobulin (Ig)α immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igβ cytoplasmic tail. J. Exp. Med. 194, 455–469 (2001).

  45. 45.

    et al. The B-cell antigen receptor integrates adaptive and innate immune signals. Proc. Natl Acad. Sci. USA 112, 12145–12150 (2015).

  46. 46.

    et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38, 475–488 (2013).

  47. 47.

    et al. Block in development at the pre-B-II to immature B cell stage in mice without Igκ and Igλ light chain. J. Immunol. 170, 1354–1361 (2003).

  48. 48.

    Dual immunoglobulin light chain B cells: Trojan horses of autoimmunity? Curr. Opin. Immunol. 27, 53–59 (2014).

  49. 49.

    et al. Basal immunoglobulin signaling actively maintains developmental stage in immature B cells. PLoS. Biol. 3, e82 (2005). This paper shows that loss of BCR expression in immature B cells leads to RAG expression and L-chain gene rearrangement, which supports a role for tonic signaling in B cell maturation.

  50. 50.

    , , & Induction of the antigen receptor expression on B lymphocytes results in rapid competence for signaling of SLP-65 and Syk. EMBO J. 17, 7304–7310 (1998).

  51. 51.

    et al. Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development. Nat. Immunol. 4, 274–279 (2003).

  52. 52.

    et al. Monovalent and multivalent ligation of the B cell receptor exhibit differential dependence upon Syk and Src family kinases. Sci. Signal. 6, ra1 (2013).

  53. 53.

    et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 13, 47–57 (2000).

  54. 54.

    , , , & Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 18, 523–533 (2003).

  55. 55.

    , , , & Regulation of B-cell development by BCAP and CD19 through their binding to phosphoinositide 3-kinase. Blood 111, 1497–1503 (2008).

  56. 56.

    , , , & B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk. eLife 3, e02069 (2014).

  57. 57.

    & Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat. Immunol. 9, 613–622 (2008). This paper shows a central role for FOXO1 in the regulation of RAG1 and RAG2 expression in B cells.

  58. 58.

    et al. Sin1-mTORC2 suppresses rag and il7r gene expression through Akt2 in B cells. Mol. Cell 39, 433–443 (2010).

  59. 59.

    et al. SLP-65 regulates immunoglobulin light chain gene recombination through the PI(3)K-PKB-Foxo pathway. Nat. Immunol. 9, 623–631 (2008).

  60. 60.

    et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573–586 (2009).

  61. 61.

    et al. BCR-mediated apoptosis associated with negative selection of immature B cells is selectively dependent on Pten. Cell Res. 19, 196–207 (2009).

  62. 62.

    , & Pten inactivation alters peripheral B lymphocyte fate and reconstitutes CD19 function. Nat. Immunol. 4, 287–294 (2003).

  63. 63.

    et al. A c-Myc/miR17-92/Pten axis controls PI3K-mediated positive and negative selection in B cell development and reconstitutes CD19 deficiency. Cell Rep. 16, 419–431 (2016).

  64. 64.

    , , & Ras activation of Erk restores impaired tonic BCR signaling and rescues immature B cell differentiation. J. Exp. Med. 207, 607–621 (2010).

  65. 65.

    , , , & The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells. J. Immunol. 185, 3239–3247 (2010).

  66. 66.

    et al. Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix protein, E2A. J. Exp. Med. 199, 1101–1112 (2004).

  67. 67.

    , , , & Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. J. Exp. Med. 206, 2271–2284 (2009).

  68. 68.

    et al. Basal B cell receptor-directed phosphatidylinositol 3-kinase signaling turns off RAGs and promotes B cell-positive selection. J. Immunol. 178, 6332–6341 (2007). This paper, together with reference 187, shows a key role for PI3K in downregulating RAG expression in newly formed B cells carrying innocuous BCRs.

  69. 69.

    et al. Negative selection by IgM superantigen defines a B cell central tolerance compartment and reveals mutations allowing escape. J. Immunol. 187, 5596–5605 (2011).

  70. 70.

    et al. B cell receptor basal signaling regulates antigen-induced Ig light chain rearrangements. J. Immunol. 180, 4728–4741 (2008).

  71. 71.

    , , & Impaired receptor editing in the primary B cell repertoire of BASH-deficient mice. J. Immunol. 173, 5980–5988 (2004).

  72. 72.

    et al. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 29, 912–921 (2008).

  73. 73.

    , , & Phosphatase regulation of immunoreceptor signaling in T cells, B cells and mast cells. Curr. Opin. Immunol. 25, 313–320 (2013).

  74. 74.

    et al. Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity 8, 497–508 (1998).

  75. 75.

    et al. Arginine methylation of the B cell antigen receptor promotes differentiation. J. Exp. Med. 207, 711–719 (2010).

  76. 76.

    et al. RAG-mediated DNA double-strand breaks activate a cell type-specific checkpoint to inhibit pre-B cell receptor signals. J. Exp. Med. 213, 209–223 (2016).

  77. 77.

    et al. The ataxia telangiectasia mutated kinase controls Igκ allelic exclusion by inhibiting secondary Vκ-to-Jκ rearrangements. J. Exp. Med. 210, 233–239 (2013).

  78. 78.

    et al. BLNK binds active H-Ras to promote B cell receptor-mediated capping and ERK activation. J. Biol. Chem. 284, 9804–9813 (2009).

  79. 79.

    et al. NF-κB activity marks cells engaged in receptor editing. J. Exp. Med. 206, 1803–1816 (2009).

  80. 80.

    et al. Development of immunoglobulin lambda-chain-positive B cells, but not editing of immunoglobulin kappa-chain, depends on NF-κB signals. Nat. Immunol. 10, 647–654 (2009).

  81. 81.

    et al. Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity 28, 335–345 (2008).

  82. 82.

    , , & A role for interferon regulatory factor 4 in receptor editing. Mol. Cell. Biol. 28, 2815–2824 (2008).

  83. 83.

    et al. A role for nuclear factor kappa B/rel transcription factors in the regulation of the recombinase activator genes. Immunity 22, 519–531 (2005).

  84. 84.

    & Receptor editing occurs frequently during normal B cell development. J. Exp. Med. 188, 1231–1238 (1998).

  85. 85.

    et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003). This paper shows that polyreactive B cells are present in humans at high frequency early in development and that this frequency is lower in more mature B cells.

  86. 86.

    , , & Light chain editing in kappa-deficient animals: a potential mechanism of B cell tolerance. J. Exp. Med. 180, 1805–1815 (1994).

  87. 87.

    & Changes in locus-specific V(D)J recombinase activity induced by immunoglobulin gene products during B cell development. J. Exp. Med. 185, 609–620 (1997).

  88. 88.

    , & Re-evaluation of the probabilities for productive arrangements on the kappa and lambda loci. Int. Immunol. 8, 91–99 (1996).

  89. 89.

    , , , & Skewed primary igkappa repertoire and v-j joining in C57BL/6 mice: implications for recombination accessibility and receptor editing. J. Immunol. 188, 2305–2315 (2012).

  90. 90.

    et al. Significant differences in physicochemical properties of human immunoglobulin kappa and lambda CDR3 regions. Front. Immunol. 7, 388 (2016).

  91. 91.

    , , & A prematurely expressed Igκ transgene, but not VκJκ gene segment targeted into the Igκ locus, can rescue B cell development in λ5-deficient mice. Immunity 5, 229–239 (1996).

  92. 92.

    , & Human autoantibody silencing by immunoglobulin light chains. J. Exp. Med. 200, 191–199 (2004).

  93. 93.

    , & Autoreactive B cells in the marginal zone that express dual receptors. J. Exp. Med. 195, 181–188 (2002).

  94. 94.

    et al. Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-1-deficient mice. Genes Dev. 8, 1030–1042 (1994).

  95. 95.

    et al. The site and stage of anti-DNA B-cell deletion. Nature 373, 252–255 (1995). The first paper to study an antibody gene knock-in model carrying both H-chain and L-chain genes with defined specificity (anti-chromatin or anti-DNA); the study shows not only that editing is nearly complete, but that it is focused on the L-chain rather than the H-chain locus.

  96. 96.

    , , , & Rearrangement of mouse immunoglobulin kappa deleting element recombining sequence promotes immune tolerance and lambda B cell production. Immunity 28, 161–170 (2008).

  97. 97.

    , , & Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection. Cell 92, 173–182 (1998).

  98. 98.

    , & Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181, 2129–2140 (1995).

  99. 99.

    et al. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J. Exp. Med. 198, 1119–1126 (2003).

  100. 100.

    et al. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 9, 35–45 (1998).

  101. 101.

    et al. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. J. Exp. Med. 186, 1513–1522 (1997).

  102. 102.

    & The FoxO code. Oncogene 27, 2276–2288 (2008).

  103. 103.

    , , & Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J. Immunol. 167, 4172–4179 (2001).

  104. 104.

    et al. STIM1, PKC-δ and RasGRP set a threshold for proapoptotic Erk signaling during B cell development. Nat. Immunol. 12, 425–433 (2011).

  105. 105.

    et al. A VH11Vκ9 B cell antigen receptor drives generation of CD5+ B cells both in vivo and in vitro. J. Immunol. 164, 4586–4593 (2000).

  106. 106.

    , , , & C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348–350 (1996).

  107. 107.

    et al. Lupus susceptibility genes may breach tolerance to DNA by impairing receptor editing of nuclear antigen-reactive B cells. J. Immunol. 179, 1340–1352 (2007).

  108. 108.

    et al. Reduced receptor editing in lupus-prone MRL/lpr mice. J. Exp. Med. 204, 2853–2864 (2007).

  109. 109.

    et al. B-Cell tolerance defects in the B6.Aec1/2 mouse model of Sjögren's syndrome. J. Clin. Immunol. 32, 551–564 (2012).

  110. 110.

    et al. B lymphocyte “original sin” in the bone marrow enhances islet autoreactivity in type 1 diabetes-prone nonobese diabetic mice. J. Immunol. 190, 5992–6003 (2013).

  111. 111.

    , , , & Autoimmune NZB/NZW F1 mice utilize B cell receptor editing for generating high-affinity anti-dsDNA autoantibodies from low-affinity precursors. Eur. J. Immunol. 33, 2469–2478 (2003).

  112. 112.

    , & The scope of receptor editing and its association with autoimmunity. Curr. Opin. Immunol. 16, 808–814 (2004).

  113. 113.

    et al. Receptor editing and genetic variability in human autoreactive B cells. J. Exp. Med. 213, 93–108 (2016).

  114. 114.

    The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann. NY Acad. Sci. 1246, 1–10 (2011). This paper reviews B cell repertoire analyses of tolerance using single-cell antibody cloning from normal donors and patients with primary immunodeficiencies.

  115. 115.

    et al. Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice. Autoimmunity 46, 188–204 (2013).

  116. 116.

    et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703–711 (2005). This paper shows major defects in B cell negative selection in patients with SLE.

  117. 117.

    & Biomarkers to guide clinical therapeutics in rheumatology? Curr. Opin. Rheumatol. 28, 168–175 (2016).

  118. 118.

    , , , & Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization. Proc. Natl Acad. Sci. USA 80, 4484–4488 (1983).

  119. 119.

    , , & B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage. Autoimmun. Rev. 6, 387–401 (2007).

  120. 120.

    et al. Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry. Arthritis Rheumatol. 68, 2210–2220 (2016).

  121. 121.

    , & High throughput cellular screens to interrogate the human T and B cell repertoires. Curr. Opin. Immunol. 23, 430–435 (2011).

  122. 122.

    & B-Cell self-tolerance in humans. Adv. Immunol. 95, 83–110 (2007).

  123. 123.

    , , , & Impaired early B cell tolerance in patients with rheumatoid arthritis. J. Exp. Med. 201, 1659–1667 (2005).

  124. 124.

    et al. Rituximab does not reset defective early B cell tolerance checkpoints. J. Clin. Invest. 126, 282–287 (2016).

  125. 125.

    et al. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. Arthritis Rheum. 65, 1085–1096 (2013).

  126. 126.

    et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J. Clin. Invest. 123, 2737–2741 (2013).

  127. 127.

    & Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu. Rev. Immunol. 12, 487–520 (1994).

  128. 128.

    et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc. Natl Acad. Sci. USA 105, 9727–9732 (2008).

  129. 129.

    et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635–3644 (2011).

  130. 130.

    & PTPN22: the archetypal non-HLA autoimmunity gene. Nat. Rev. Rheumatol. 10, 602–611 (2014).

  131. 131.

    et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 123, 2024–2036 (2013).

  132. 132.

    et al. PTPN22 inhibition resets defective human central B cell tolerance. Sci. Immunol. 1, aaf7153 (2016).

  133. 133.

    et al. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J. Clin. Invest. 122, 2141–2152 (2012).

  134. 134.

    et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J. Exp. Med. 207, 1541–1554 (2010).

  135. 135.

    et al. CVID-associated TACI mutations affect autoreactive B cell selection and activation. J. Clin. Invest. 123, 4283–4293 (2013).

  136. 136.

    et al. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381, 325–328 (1996).

  137. 137.

    et al. Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. J. Allergy Clin. Immunol. 127, 538–541 (2011).

  138. 138.

    & Cracking the BAFF code. Nat. Rev. Immunol. 9, 491–502 (2009).

  139. 139.

    et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29, 746–757 (2008).

  140. 140.

    et al. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J. Immunol. 190, 1447–1456 (2013).

  141. 141.

    et al. Activation-induced cytidine deaminase expression in human B cell precursors is essential for central B cell tolerance. Immunity 43, 884–895 (2015).

  142. 142.

    et al. Activation-induced cytidine deaminase mediates central tolerance in B cells. Proc. Natl Acad. Sci. USA 108, 11560–11565 (2011).

  143. 143.

    et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906–1908 (2005).

  144. 144.

    , & HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 10, e1004073 (2014).

  145. 145.

    et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 21, 86–91 (2015).

  146. 146.

    et al. Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. J. Exp. Med. 191, 1443–1448 (2000).

  147. 147.

    et al. Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization. Immunity 17, 451–462 (2002).

  148. 148.

    , , , & Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs. PLoS ONE 8, e54938 (2013).

  149. 149.

    et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463, 88–92 (2010).

  150. 150.

    & Antigen presentation by the B cell antigen receptor is driven by the alpha/beta sheath and occurs independently of its cytoplasmic tyrosines. Cell 74, 939–946 (1993).

  151. 151.

    et al. The B lymphocyte adaptor molecule of 32 kilodaltons (Bam32) regulates B cell antigen receptor internalization. J. Immunol. 173, 5601–5609 (2004).

  152. 152.

    et al. Visualization of Syk-antigen receptor interactions using green fluorescent protein: differential roles for Syk and Lyn in the regulation of receptor capping and internalization. J. Immunol. 166, 1507–1516 (2001).

  153. 153.

    , & Igβ tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization. J. Exp. Med. 203, 1785–1794 (2006).

  154. 154.

    , , & Role of Syk in B-cell development and antigen-receptor signaling. Proc. Natl Acad. Sci. USA 97, 1713–1718 (2000).

  155. 155.

    et al. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26, 567–578 (2007).

  156. 156.

    et al. The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85. EMBO J. 30, 3620–3634 (2011).

  157. 157.

    et al. CIN85 drives B cell responses by linking BCR signals to the canonical NF-κB pathway. J. Exp. Med. 208, 1447–1457 (2011).

  158. 158.

    , , , & Bam32 links the B cell receptor to ERK and JNK and mediates B cell proliferation but not survival. Immunity 19, 621–632 (2003).

  159. 159.

    et al. B cell antigen receptor signaling and internalization are mutually exclusive events. PLoS Biol. 4, e200 (2006).

  160. 160.

    et al. The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nat. Immunol. 17, 433–440 (2016).

  161. 161.

    et al. Regulation of B-cell development and tolerance by different members of the miR-17 approximately 92 family microRNAs. Nat. Commun. 7, 12207 (2016).

  162. 162.

    The pre-B-cell receptor: selector of fitting immunoglobulin heavy chains for the B-cell repertoire. Nat. Rev. Immunol. 5, 578–584 (2005).

  163. 163.

    et al. A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat. Immunol. 13, 300–307 (2012).

  164. 164.

    et al. VH replacement in primary immunoglobulin repertoire diversification. Proc. Natl Acad. Sci. USA 112, E458–E466 (2015).

  165. 165.

    et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J. Exp. Med. 188, 2151–2162 (1998).

  166. 166.

    , , & The human immunoglobulin κ locus on yeast artificial chromosomes (YACs). Gene 191, 173–181 (1997).

  167. 167.

    et al. Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2. Hum. Mol. Genet. 4, 983–991 (1995).

  168. 168.

    , , , & Clustered arrangement of immunoglobulin lambda constant region genes in man. Nature 294, 536–540 (1981).

  169. 169.

    et al. Responsiveness of B cells is regulated by the hinge region of IgD. Nat. Immunol. 16, 534–543 (2015).

  170. 170.

    et al. Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol. Cell 10, 1057–1069 (2002).

  171. 171.

    et al. The physiologic role of CD19 cytoplasmic tyrosines. Immunity 17, 501–514 (2002).

  172. 172.

    Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31, 675–704 (2013).

  173. 173.

    et al. SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J. Exp. Med. 188, 791–795 (1998).

  174. 174.

    New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat. Rev. Immunol. 13, 578–591 (2013).

  175. 175.

    & B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Rep. 5, 40 (2013).

  176. 176.

    , , , & Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 200, 927–934 (2004).

  177. 177.

    et al. Bruton's tyrosine kinase regulates the activation of gene rearrangements at the λ light chain locus in precursor B cells in the mouse. J. Exp. Med. 193, 1169–1178 (2001).

  178. 178.

    & Cellular maturation defects in Bruton's tyrosine kinase-deficient immature B cells are amplified by premature B cell receptor expression and reduced by receptor editing. J. Immunol. 172, 1371–1379 (2004).

  179. 179.

    & Co-receptor and accessory regulation of B-cell antigen receptor signal transduction. Immunol. Rev. 160, 127–138 (1997).

  180. 180.

    , , , & Modification of ligand-independent B cell receptor tonic signals activates receptor editing in immature B lymphocytes. J. Biol. Chem. 279, 13418–13424 (2004).

  181. 181.

    , & Receptor editing in CD45-deficient immature B cells. Eur. J. Immunol. 32, 2264–2273 (2002).

  182. 182.

    et al. CIN85 is required for Cbl-mediated regulation of antigen receptor signaling in human B cells. Blood 119, 2263–2273 (2012).

  183. 183.

    et al. Overexpression of Fkbp11, a feature of lupus B cells, leads to B cell tolerance breakdown and initiates plasma cell differentiation. Immun. Inflamm. Dis. 3, 265–279 (2015).

  184. 184.

    et al. Role of tyrosine phosphorylation of HS1 in B cell antigen receptor-mediated apoptosis. J. Exp. Med. 185, 1387–1392 (1997).

  185. 185.

    , , , & Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways. Immunol. Lett. 135, 74–77 (2011).

  186. 186.

    et al. Activation of Ras overcomes B-cell tolerance to promote differentiation of autoreactive B cells and production of autoantibodies. Proc. Natl Acad. Sci. USA 111, E2797–E2806 (2014).

  187. 187.

    , , , & The PI3K p110δ is required for down-regulation of RAG expression in immature B cells. J. Immunol. 178, 1981–1985 (2007). This paper shows the importance of the PI3K pathway in downregulating RAG expression in immature B cells, and defines p110δ as a key player in positive selection.

  188. 188.

    et al. Phospholipase Cγ2 contributes to light-chain gene activation and receptor editing. Mol. Cell. Biol. 27, 5957–5967 (2007).

  189. 189.

    , , , & Multiple checkpoint breach of B cell tolerance in Rasgrp1-deficient mice. J. Immunol. 191, 3605–3613 (2013).

  190. 190.

    et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378, 303–306 (1995).

  191. 191.

    et al. Syk tyrosine kinase is required for the positive selection of immature B cells into the recirculating B cell pool. J. Exp. Med. 186, 2013–2021 (1997).

Download references

Acknowledgements

The author thanks current and former members of his laboratory, The Scripps Research Institute Department of Immunology and Microbial Science, and the following funding sources: US Department of Health & Human Services, National Institutes of Health (NIH) grants R37AI059714, R01AI128836 and R01AI073148.

Author information

Affiliations

  1. Department of Immunology and Microbial Science, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.

    • David Nemazee

Authors

  1. Search for David Nemazee in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to David Nemazee.

Glossary

CD4+ T follicular helper (TFH) cells

CD4+ T cells that are specialized to interact with B cells to promote and maintain the germinal centre reaction.

Systemic lupus erythematosus

(SLE). A prototypical autoimmune disease characterized by B cell hyperactivity, autoantibody production and a range of symptoms that can include vasculitis, arthritis, glomerulonephritis, fever and neurological abnormalities.

Anergy

Functional impairment of B or T cells resulting from prolonged signalling, usually caused by self-recognition.

Receptor editing

A process whereby ongoing antibody gene recombination promotes a change in the specificity or expression of the antigen receptor of a B cell; receptor editing is usually associated with central tolerance.

Immunoreceptor tyrosine-based activation motifs

(ITAMs). Conserved motifs (YXXL/IX(6–8)YXXL/I) on the cytoplasmic tails of CD79A–CD79B, CD3 proteins and other immune system proteins that become phosphorylated upon receptor ligation and recruit SYK and ZAP70.

Allelic exclusion

The phenomenon of expression of only one of two alleles despite the genetic potential to express both. In normal B cells, expression of both alleles of the heavy chain occurs at a frequency of 0.0001%, and the frequency of light-chain double expression is 1%.

Positive selection

In the context of B cell development, this refers to the process whereby immature B cells progress from a programme of active light chain gene recombination to a more mature phenotype, which is associated with the cessation of recombination and migration from bone marrow.

Tonic signal

The weak signal emanating from a receptor in the absence of its ligand.

Recombination-activating genes

RAG1 and RAG2 have non-redundant roles in initiating V(D)J recombination at recombination signal sequences through their DNA binding and nuclease activities.

Pre-BCR

(Pre-B cell receptor). The complex formed when an immunoglobulin heavy chain pairs with the surrogate light-chain components 5 and Vpre-B, allowing surface expression of a complex including CD79A–CD79B and other signalling components.

BCR capping

(B cell receptor capping). Theprocess whereby antigen receptors on B cells redistribute and aggregate on the plasma membrane after antigen recognition.

IgM macroself mice

Transgenic mice expressing a custom-designed superantigen reactive to the constant region of IgM, derived from a fusion protein of single-chain antibody fused to a part of the IgG extracellular region and transmembrane and cytoplasmic regions of an MHC class I molecule.

MicroRNAs

(miRNAs). Short (22 bp) RNAs that function by downregulating mRNA translation or stability and that have important roles in many cellular pathways.

Humanized mice

Severe combined immunodeficient (SCID) mice transplanted with haematopoietic cells from humans. These mice are useful for carrying out experiments on human immune cells in vivo.

λ-Locus excision circles

Intervening DNA removed and religated to itself by V-to-J rearrangement in the immunoglobulin λ locus.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nri.2017.19

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing